US 12,421,284 B2
Chimeric neurotoxins
Sai Man Liu, Wrexham (GB)
Assigned to IPSEN BIOPHARM LIMITED, Wrexham (GB)
Filed by IPSEN BIOPHARM LIMITED, Wrexham (GB)
Filed on Jul. 12, 2022, as Appl. No. 17/811,958.
Application 17/811,958 is a division of application No. 16/094,254, granted, now 11,434,265, previously published as PCT/EP2017/060821, filed on May 5, 2017.
Claims priority of application No. 1607901 (GB), filed on May 5, 2016.
Prior Publication US 2023/0025090 A1, Jan. 26, 2023
Int. Cl. C07K 14/33 (2006.01); C12N 9/52 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/33 (2013.01) [C12N 9/52 (2013.01); C12Y 304/24069 (2013.01); A61K 38/00 (2013.01); C07K 2319/55 (2013.01)] 20 Claims
 
1. A nucleic acid sequence encoding a chimeric neurotoxin comprising a LHN domain from a first neurotoxin covalently linked to a HC domain from a second neurotoxin, wherein:
the first and second neurotoxins are different;
the C-terminal amino acid residue of said LHN domain corresponds to the first amino acid residue of the 310 helix separating the LHN and HC domains in said first neurotoxin; and
the N-terminal amino acid residue of the HC domain corresponds to the second amino acid residue of the 310 helix separating the LHN and HC domains in the second neurotoxin.